# CJC-1295 Side Effects in the Research Literature > CJC-1295 side effects documented in the Phase I human trial, the FDA Pharmacy Compounding Advisory Committee briefing, and the broader GH/IGF-1 axis literature. _Injection-site reactions, flushing, cardiovascular signals, and the FDA cardiovascular advisory — what the published record says and where it stops._ ## What the Phase I record reported CJC-1295 side effects in the published record come almost entirely from one source: the Teichman 2006 Phase I dose-escalation trial in healthy adults [6]. The trial reported the molecule as safe and relatively well tolerated, particularly at the lower 30 and 60 µg/kg doses, with no serious adverse reactions across the cohort [6]. Documented events included injection-site reactions (pain, redness, transient swelling) and transient flushing or warmth, both consistent with the systemic vasodilation expected from GH-axis activation [6][14]. No long-term human safety data exist. The Teichman trial measured single-dose and short repeat-dose safety in healthy adults; chronic-dose safety in any population has not been published. The ConjuChem Phase II HIV-lipodystrophy trial (n = 192) was halted in 2006 after a participant death from myocardial infarction — the investigator clinically attributed the event to pre-existing asymptomatic coronary artery disease rather than to study drug, but commercial development of CJC-1295 was discontinued at that point and no further safety data have been generated under controlled-trial conditions [13]. ## Reported side effects of CJC-1295 ### Reported side effects of CJC-1295 Reported in trials and pharmacy literature: injection-site reactions (pain, redness, flushing), headache, vertigo, drowsiness, transient increases in heart rate [6][14]. The FDA has flagged cardiovascular concerns including increased heart rate and systemic vasodilation in its 2024 Pharmacy Compounding Advisory Committee briefing materials [14]. ## Is CJC-1295 safe? ### Is CJC-1295 safe? Not FDA-approved for any clinical indication [14][17]. Phase I human trials reported the molecule was generally well tolerated, but long-term safety data in humans do not exist; the FDA has issued advisories about cardiovascular and off-label use risks for compounded peptides [14]. WADA prohibits the substance at all times under category S2 [15]. ## Long-term side effects ### Long-term side effects No long-term human data exist [1]. Theoretical concerns extrapolated from sustained GH/IGF-1 elevation in the broader GH-therapy literature include insulin resistance, edema, arthralgias, and carpal tunnel syndrome at higher doses [16]. Per FDA-advisory framing: cardiovascular effects (increased heart rate, systemic vasodilation) are flagged class concerns [14]. ## The FDA cardiovascular advisory, in full context In the FDA's 2024 Pharmacy Compounding Advisory Committee (PCAC) briefing materials, CJC-1295 was characterized as presenting safety concerns including increased heart rate and systemic vasodilatory reactions — flushing, warmth, and transient hypotension — supporting categorization away from 503A compounding eligibility pending review [14]. The PCAC voted against recommending most reviewed peptides for inclusion on the 503A bulks list; CJC-1295 was placed in Category 2 in September 2023 and removed in September 2024 after sponsors withdrew their nominations [14][17]. The regulatory finding is consistent with the pharmacology. GHRH-analog activity raises growth-hormone secretion, and growth hormone has known vasodilatory and cardiac-rate effects; the Phase I trial documented flushing and minor heart-rate signals at the higher 125 and 250 µg/kg doses [6]. What the FDA materials add is the institutional flag — they do not constitute a new clinical-trial dataset, but they establish that the regulator views the cardiovascular signal as substantial enough to keep the substance outside routine compounding eligibility [14]. ## Adverse-event signals from the GH/IGF-1-axis literature Long-term elevation of the GH/IGF-1 axis — the pharmacological endpoint CJC-1295 produces — is associated in the broader growth-hormone-therapy literature with insulin resistance, peripheral edema, arthralgias, and carpal tunnel syndrome at higher doses [16]. A 2022 analysis of 15,809 GH-treated adults found these adverse-event categories were dose-dependent, partially transient, and well-characterized in the GH-replacement population [16]. This is class context, not CJC-1295-specific data. The compound has not been studied at chronic supraphysiological doses in any controlled trial; the inference from GH-treatment literature is that sustained GH/IGF-1 elevation at supraphysiological levels would be expected to produce a similar adverse-event spectrum. Tesamorelin, the only FDA-approved GHRH analog, reported injection-site erythema and pruritus, arthralgias, peripheral edema, and transient hyperglycemia as its most common Phase III adverse events at 2 mg/day SC — the same class-effect spectrum [11][18]. ## Are there long-term side effects from CJC-1295? ### Are there long-term side effects from CJC-1295? No long-term human data exist [1]. Theoretical concerns from sustained GH/IGF-1 elevation, drawn from the broader GH-therapy literature, include insulin resistance, edema, carpal tunnel syndrome, and — per the FDA PCAC advisory — cardiovascular effects [14][16]. ## What the record does not establish The CJC-1295 side-effects record does not contain a chronic-dose safety study in any population. It does not contain immunogenicity data on compounded preparations from any specific pharmacy. It does not contain cancer-incidence follow-up, which is a relevant concern any time the IGF-1 axis is sustainedly elevated [16]. The FDA PCAC briefing flagged impurity and immunogenicity risks for compounded peptides as a class; the agency specifically noted that purity, peptide identity, and concentration vary across compounding-pharmacy 'CJC-1295/ipamorelin' formulations [14]. This is a manufacturing-quality concern distinct from the drug's own pharmacological side-effect profile, but it is part of the public-record safety picture for anyone reading the dossier honestly. ## References [1] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/ [6] Teichman SL, et al. Safety and tolerability of CJC-1295 in Phase I dose escalation — no serious adverse reactions; injection-site reactions and transient flushing reported. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/ [11] Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. https://www.nejm.org/doi/full/10.1056/NEJMoa072375 [13] Aidsmap editorial. Lipodystrophy study halted after patient death (news report on ConjuChem Phase II CJC-1295 trial). aidsmap.com. 2006. https://www.aidsmap.com/news/jul-2006/lipodystrophy-study-halted-after-patient-death [14] U.S. Food and Drug Administration. FDA Briefing Document — Pharmacy Compounding Advisory Committee (PCAC) Meeting on peptide bulk drug substances. 2024. https://www.fda.gov/media/183819/download [15] World Anti-Doping Agency. The Prohibited List — International Standard (Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics). WADA Prohibited List 2026. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf [16] Johannsson G, Touraine P, Feldt-Rasmussen U, et al. Long-term safety of growth hormone in adults with growth hormone deficiency: overview of 15,809 GH-treated patients. J Clin Endocrinol Metab. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9202689/ [17] Lexology editorial. FDA removes certain peptide bulk drug substances from Category 2 of interim 503A bulks list and sets dates for PCAC review. 2024. https://www.lexology.com/library/detail.aspx?g=2e55b76a-3173-4e04-beda-bf021202f18d [18] Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. https://jamanetwork.com/journals/jama/fullarticle/1889139 --- A compounding-pharmacy reading room for the CJC-1295 research record — Phase I evidence rendered in solid rules, gray-literature claims in dashed ones, no scripts filled on the premises.